Can Evolus Disrupt the Botox Market?

The facial injections industry is estimated to be valued at $13.4 billion and is expected to grow at an 8.8% compound annual growth rate until 2028. The leader in facial injections is the well-known Botox product, which was invented by Allergan, a company now owned by biotechnology giant AbbVie (NYSE: ABBV). The product wins over $1 billion in sales a year just in cosmetics (non-medical injections). However, a product from performance beauty company Evolus (NASDAQ: EOLS) called Jeuveau is looking to shake up the facial injections market. Does Evolus have what it takes?

Image source: Getty Images.

Jeuveau is an injectable serum containing the botulinum toxin type A compound, the same active ingredient that's in Botox and other facial injection products. In 2019, the U.S. Food and Drug Administration (FDA) approved the use of Jeuveau for glabellar lines (wrinkles in between the eyebrows). Evolus is looking to get approval for other areas of the body in the future.

Source Fool.com

Like: 0

EOLS

Teilen

TheMotleyFool

Rechtlicher Hinweis

Kommentare

While Botox remains popular, many people myself included are starting to explore regenerative treatments that go beyond just freezing muscles. One such option is the Rejuran Healer, which focuses on skin rejuvenation at a cellular level rather than just surface-level fixes. I recently came across https://skin-reboot.com/product/rejuran-healer/ and was pleasantly surprised by the rejuran healer price which is quite reasonable compared to long-term Botox sessions. It’s refreshing to see more consumers shifting towards options that actually improve skin health over time. If Evolus continues to innovate, and more natural therapies like Rejuran gain popularity, the beauty market might look very different in just a few years.